c-MET NSCLC FDA Approvals, Clinical Trials Assessment, Pipeline Insights, and Companies
DelveInsight's, 'C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Pipeline Insight' report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in C-MET Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the c-MET-NSCLC Treatment Landscape. Click here to read more @ c-MET-NSCLC Pipeline Outlook
Key Takeaways from the c-MET-NSCLC Pipeline Report
In January 2025:- AbbVie:- A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer.
DelveInsight's c-MET-NSCLC pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for c-MET-NSCLC treatment.
The leading c-MET-NSCLC Companies such as AbbVie, Janssen Research & Development, Beijing Pearl Biotechnology Limited Liability Company, Novartis, and others.
Promising C-MET NSCLC Therapies such as Glumetinib, Tepotinib, INC280, APL-101 Oral Capsules, MCLA-129, Osimertinib, and others.
Stay informed about the cutting-edge advancements in c-MET NSCLC treatments. Download for updates and be a part of the revolution in cancer care @ c-MET NSCLC Clinical Trials Assessment
c-MET NSCLC Emerging Drugs Profile
JNJ-61186372: Janssen Research & Development, LLC
JNJ-6372 is an EGFR-MET bispecific antibody with immune cell-directing activity that targets activating and resistant EGFR and MET mutations and amplifications. The production and development of the antibody followed Janssen's licensing agreement with Genmab for use of its DuoBody technology platform. According to the company, JNJ-6372 is a novel bispecific antibody that has the potential to benefit patients with Exon 20 mutation insertions who often do not respond to currently available oral EGFR-targeted or immune checkpoint inhibitor therapies.
PLB1001 - Beijing Pearl Biotechnology Limited Liability Company
PLB1001 is an orally bioavailable inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) with potential antineoplastic activity. Upon administration, PLB1001 selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.
c-MET NSCLC Companies
AbbVie, Janssen Research & Development, Beijing Pearl Biotechnology Limited Liability Company, Novartis, and others.
C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Intramuscular
Intratumoral
Intravenous
Molecule Type
c-MET NSCLC Products have been categorized under various Molecule types such as
Gene therapies
Bispecific antibodies
Immunotherapies
Monoclonal antibodies
Small molecules
Product Type
Discover the latest advancements in c-MET NSCLC treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ c-MET NSCLC Market Drivers and Barriers, and Future Perspectives
Scope of the c-MET NSCLC Pipeline Report
Coverage- Global
c-MET NSCLC Companies- AbbVie, Janssen Research & Development, Beijing Pearl Biotechnology Limited Liability Company, Novartis, and others.
C-MET NSCLC Therapies- Glumetinib, Tepotinib, INC280, APL-101 Oral Capsules, MCLA-129, Osimertinib, and others.
c-MET NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
c-MET NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of c-MET NSCLC Pipeline on our website @ c-MET NSCLC Emerging Drugs and Companies
Table of Content
Introduction
Executive Summary
C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC): Overview
Pipeline Therapeutics
Therapeutic Assessment
C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) – DelveInsight's Analytical Perspective
In-depth Commercial Assessment
C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Collaboration Deals
Mid Stage Products (Phase II)
Telisotuzumab: AbbVie
PLB1001: Beijing Pearl Biotechnology Limited Liability Company
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
JNJ-61186372: Janssen Research & Development, LLC
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Drug profiles in the detailed report…..
Inactive Products
C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Key Companies
C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Key Products
C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC)- Unmet Needs
C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC)- Market Drivers and Barriers
C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC)- Future Perspectives and Conclusion
C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Analyst Views
C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/testicular-cancer-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Winnipeg Free Press
a day ago
- Winnipeg Free Press
What it would take to convert a jet from Qatar into Air Force One to safely fly Trump
WASHINGTON (AP) — President Donald Trump really wants to fly on an upgraded Air Force One — but making that happen could depend on whether he's willing to cut corners with security. As government lawyers sort out the legal arrangement for accepting a luxury jet from the Qatari royal family, another crucial conversation is unfolding about modifying the plane so it's safe for the American president. Installing capabilities equivalent to the decades-old 747s now used as Air Force One would almost certainly consign the project to a similar fate as Boeing's replacement initiative, which has been plagued by delays and cost overruns. Air Force Secretary Troy Meink told lawmakers Thursday that those security modifications would cost less than $400 million but provided no details. Satisfying Trump's desire to use the new plane before the end of his term could require leaving out some of those precautions, however. A White House official said Trump wants the Qatari jet ready as soon as possible while adhering to security standards. The official, who spoke on the condition of anonymity, did not provide details on equipment issues or the timeline. Trump has survived two assassination attempts, and Iran allegedly also plotted to kill him, so he's well aware of the danger he faces. However, he seems willing to take some chances with security, particularly when it comes to communications. For example, he likes to keep his personal phone handy despite the threat of hacks. He boasted this week that the government got the jet 'for free,' saying, 'We need it as Air Force One until the other ones are done.' Here's a look at what it would take to make the Qatari plane into a presidential transport: What makes a plane worthy of being Air Force One? Air Force One is the call sign for any plane that's carrying the president. The first aircraft to get the designation was a propeller-powered C-54 Skymaster, which ferried Franklin D. Roosevelt to the Yalta Conference in 1945. It featured a conference room with a bulletproof window. Things are a lot more complicated these days. Boeing has spent years stripping down and rebuilding two 747s to replace the versions that have carried presidents for more than three decades. The project is slated to cost more than $5.3 billion and may not be finished before Trump leaves office. A 2021 report made public through the Freedom of Information Act outlines the unclassified requirements for the replacement 747s under construction. At the top of the list — survivability and communications. The government decided more than a decade ago that the new planes had to have four engines so they could remain airborne if one or two fail, said Deborah Lee James, who was Air Force secretary at the time. That creates a challenge because 747s are no longer manufactured, which could make spare parts harder to come by. Air Force One also has to have the highest level of classified communications, anti-jamming capabilities and external protections against foreign surveillance, so the president can securely command military forces and nuclear weapons during a national emergency. It's an extremely sensitive and complex system, including video, voice and data transmissions. James said there are anti-missile measures and shielding against radiation or an electromagnetic pulse that could be caused by a nuclear blast. 'The point is, it remains in flight no matter what,' she said. Will Trump want all the security bells and whistles? If the Qatari plane is retrofitted to presidential standards, it could cost $1.5 billion and take years, according to a U.S. official who spoke on the condition of anonymity to provide details that aren't publicly available. Testifying before Congress this week, Meink discounted such estimates, arguing that some of the costs associated with retrofitting the Qatari plane would have been spent anyway as the Air Force moves to build the long-delayed new presidential planes, including buying aircraft for training and to have spares available if needed. In response, Rep. Joe Courtney, D-Conn., said that based on the contract costs for the planes that the Air Force is building, it would cost about $1 billion to strip down the Qatar plane, install encrypted communications, harden its defenses and make other required upgrades. James said simply redoing the wiring means 'you'd have to break that whole thing wide open and almost start from scratch.' Trump, as commander in chief, could waive some of these requirements. He could decide to skip shielding systems from an electromagnetic pulse, leaving his communications more vulnerable in case of a disaster but shaving time off the project. After all, Boeing has already scaled back its original plans for the new 747s. Their range was trimmed by 1,200 nautical miles, and the ability to refuel while airborne was scrapped. Paul Eckloff, a former leader of protection details at the Secret Service, expects the president would get the final say. 'The Secret Service's job is to plan for and mitigate risk,' he said. 'It can never eliminate it.' If Trump does waive some requirements, James said that should be kept under wraps because 'you don't want to advertise to your potential adversaries what the vulnerabilities of this new aircraft might be.' It's unlikely that Trump will want to skimp on the plane's appearance. He keeps a model of a new Air Force One in the Oval Office, complete with a darker color scheme that echoes his personal jet instead of the light blue design that's been used for decades. What happens next? Trump toured the Qatari plane in February when it was parked at an airport near Mar-a-Lago, his Florida resort. Air Force chief of staff Gen. David Allvin was there, too. The U.S. official said the jet needs maintenance but not more than what would be expected of a four-engine plane of its complexity. Sen. Tammy Duckworth, an Illinois Democrat on the Senate Armed Services Committee, said it would be irresponsible to put the president and national security equipment aboard the Qatari plane 'without knowing that the aircraft is fully capable of withstanding a nuclear attack.' 'It's a waste of taxpayer dollars,' she said. Meanwhile, Boeing's project has been hampered by stress corrosion cracks on the planes and excessive noise in the cabins from the decompression system, among other issues that have delayed delivery, according to a Government Accountability Office report released last year. Boeing referred questions to the Air Force, which said in a statement that it's working with the aircraft manufacturer to find ways to accelerate the delivery of at least one of the 747s. Even so, the aircraft will have to be tested and flown in real-world conditions to ensure no other issues. James said it remains to be seen how Trump would handle any of those challenges. 'The normal course of business would say there could be delays in certifications,' she said. 'But things seem to get waived these days when the president wants it.' ___ AP writer Lolita C. Baldor in Washington contributed to this report.
CTV News
2 days ago
- CTV News
Appeal filed against proposed Exchange District development
The Sanford Building and Maw's Garage in Winnipeg's Exchange District are both pictured in April 2025. (Michelle Gerwing/CTV News Winnipeg) A city committee will hear an appeal to a proposed addition to two Exchange District heritage buildings next week. According to the property and development committee's agenda, the president of a nearby condo complex has appealed the decision to create a nine-storey rooftop addition above the Sanford Building and Maw's Garage near Bannatyne Avenue and King Street. In a letter, Alan Tate said the proposed development is out of scale and out of character for the area, and would impact the proposed development of the Exchange District as a National Historic Site. The letter also claims the development could physically impact neighbouring structures, particularly his own building on Princess Street. A permit was granted for the project in April by the same committee. The matter will be heard when the committee meets June 11.
Toronto Star
4 days ago
- Toronto Star
Check-Cap claims BMO's Chris Taves Illegally Attacks Israeli NASDAQ-Listed Company During Wartime
Check-Cap Ltd. Issues Strong Condemnation of MediPharm Labs Chairman Chris Taves for Fabricated Defamatory Statements Press Releases Taves Times his Attack to Commence 23 Minutes before the Start of Shabbat to Delay the Company from Responding ISFIYA, ISRAEL, June 04, 2025 (GLOBE NEWSWIRE) — Check-Cap Ltd. (NASDAQ: CHEK) ('Check-Cap' or the 'Company'), a clinical-stage medical diagnostics company incorporated in Israel, today publicly condemned MediPharm Labs Corp. (LABS) ('MediPharm Labs') and its Chairman, Chris Taves, Head of Asia for BMO Capital Markets, for disseminating derogatory, false, and misleading statements about Check-Cap during a profoundly sensitive and challenging time for Israeli Companies. ARTICLE CONTINUES BELOW Check-Cap is deeply disturbed that Mr. Taves would leverage the implied authority of his position as a senior BMO Executive to exploit the wartime circumstances currently affecting Israel, in order to knowingly spread false information aimed at harming Check-Cap's reputation, stock price, and business relationships. This conduct is not only unethical and unlawful - it is shameful. Specifically, MediPharm Labs's May 23, 2025 press release quoted Mr. Taves making what Check Cap believes to be demonstrably false statements about Check-Cap. Even more egregious, Mr. Taves, a financial executive who surely knows better, publicly disseminated his accusation of there being deficiencies in our public disclosures, without any actual factual basis whatsoever. Check-Cap believes that Mr. Taves is misusing his position of trust as a BMO Capital Markets Executive to intentionally issue these misleading statements during trading hours in order to manipulate and drive down Check-Cap's stock price, violating Section 9(a)(2) of the U.S. Securities Exchange Act of 1934. Check-Cap demands that MediPharm Labs and Mr. Taves immediately retract the defamatory press release, cease all related misleading communications, and publicly apologize for Mr. Taves disgraceful actions. The fact that Mr. Taves and MediPharm Labs have chosen to launch such deplorable and unfounded attacks on an Israeli company minutes before the start of Shabbat at a time of war is reprehensible. Check-Cap will vigorously defend its reputation and its rights against these highly unethical attempts at aspersion, market manipulation and interference in a public transaction. About Check-Cap Check-Cap (NASDAQ: CHEK) is a clinical stage medical diagnostics company aiming to redefine colorectal cancer (CRC) screening through the introduction of C-Scan®, the first and only patient-friendly preparation-free screening test to detect polyps before they may transform into colorectal cancer and enable early intervention and cancer prevention. C-Scan is an investigational device and is not available for sale in the United States. ARTICLE CONTINUES BELOW ARTICLE CONTINUES BELOW Legal Notice Regarding Forward-Looking Statements This press release contains 'forward-looking statements' about the Company's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. Words such as 'may,' 'should,' 'could,' 'would,' 'predicts,' 'potential,' 'continue,' 'expects,' 'anticipates,' 'future,' 'intends,' 'plans,' 'believes,' 'estimates,' and similar expressions, as well as statements in future tense, often signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information that the Company has when those statements are made or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. For a discussion of these and other risks that could cause such differences and that may affect the realization of forward-looking statements, please refer to the 'Forward-looking Statements' and 'Risk Factors' in the Company's Annual Report on Form 20-F for the year endedDecember 31, 2023and other filings with the Securities and Exchange Commission (SEC). Investors and security holders are urged to read these documents free of charge on the SEC's web site at The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. info@
